When it comes to President Donald Trump’s plans to bring down drug prices, the market has come to its own conclusions.
Once, two sentences in a 6,500-word Time “Person of the Year” profile was enough to
But since Trump’s late January meeting with pharmaceutical executives, investors have done an about-face on the sector.
But after the president’s pharmaceutical meeting, when Trump said again that drug prices needed to be lower but appeared
The SPDR S&P Pharmaceuticals ETF’s trajectory in the month since has gone steadily up, an 11.8% surge.
Though Trump said drug prices were “astronomical” at the late January meeting, and later that day White House press secretary Sean Spicer reasserted interest in negotiating drug prices, the key takeaway for many has been the president’s focus on what other countries pay for drugs.
Other countries, many...